CLINICAL RESEARCH: HYPERTROPHIC CARDIOMYOPATHY
Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy
Iacopo Olivotto, MD*,*,
Martin S. Maron, MD ,
Camillo Autore, MD ,
John R. Lesser, MD ,
Luigi Rega, MD*,
Giancarlo Casolo, MD*,
Marcello De Santis, MD ,
Giovanni Quarta, MD ,
Stefano Nistri, MD*,
Franco Cecchi, MD*,
Carol J. Salton, BA||,
James E. Udelson, MD ,
Warren J. Manning, MD|| and
Barry J. Maron, MD
* Regional Referral Center for Myocardial Diseases and Radiology Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
Cardiology and Radiology Units, Ospedale Sant'Andrea, Università di Roma "La Sapienza," Rome, Italy
Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Division of Cardiology, Tufts-New England Medical Center, Boston, Massachusetts
|| Department of Medicine (Cardiovascular Division) and Radiology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts.
Manuscript received January 17, 2008;
revised manuscript received April 17, 2008,
accepted April 28, 2008.
* Reprint requests and correspondence: Dr. Iacopo Olivotto, Centro di Riferimento per le Cardiomiopatie, Cardiologia San Luca, Azienda Ospedaliera Universitaria Careggi, Viale Pieraccini 19, 50134 Firenze, Italy. (Email: olivottoi{at}ao-careggi.toscana.it).
Objectives: Our aim was to assess the distribution and clinical significance of left ventricular (LV) mass in patients with hypertrophic cardiomyopathy (HCM).
Background: Hypertrophic cardiomyopathy is defined echocardiographically by unexplained left ventricular wall thickening. Left ventricular mass, quantifiable by modern cardiovascular magnetic resonance techniques, has not been systematically assessed in this disease.
Methods: In 264 HCM patients (age 43 ± 18 years; 75% men), LV mass by cardiovascular magnetic resonance was measured, indexed by body surface area, and compared with that in 606 healthy control subjects.
Results: The LV mass index in HCM patients significantly exceeded that of control subjects (104 ± 40 g/m2 vs. 61 ± 10 g/m2 in men and 89 ± 33 g/m2 vs. 47 ± 7 g/m2 in women; both p < 0.0001). However, values were within the normal range ( mean +2 SDs for control subjects) in 56 patients (21%), and only mildly increased (mean +2 to 3 SDs) in 18 (16%). The LV mass index showed a modest relationship to maximal LV thickness (r2 = 0.38; p < 0.001), and was greater in men (104 ± 40 g/m2 vs. 89 ± 33 g/m2 in women; p < 0.001) and in patients with resting outflow obstruction (121 ± 43 g/m2 vs. 96 ± 37 g/m2 in nonobstructives; p < 0.001). During a 2.6 ± 0.7-year follow-up, markedly increased LV mass index proved more sensitive in predicting outcome (100%, with 39% specificity), whereas maximal wall thickness >30 mm was more specific (90%, with 41% sensitivity).
Conclusions: In distinction to prior perceptions, LV mass index was normal in about 20% of patients with definite HCM phenotype. Therefore, increased LV mass is not a requirement for establishing the clinical diagnosis of HCM. The LV mass correlated weakly with maximal wall thickness, and proved more sensitive in predicting outcome.
Key Words: hypertrophic cardiomyopathy cardiac magnetic resonance left ventricular mass hypertrophy outcome
|
Abbreviations and Acronyms
| | BSA = body surface area | | CMR = cardiovascular magnetic resonance | | HCM = hypertrophic cardiomyopathy | | LV = left ventricle/ventricular | | OR = odds ratio |
|
Related Articles
-
Hypertrophic Cardiomyopathy: Cardiac Magnetic Resonance Imaging Changes the Paradigm
- Nathaniel Reichek and Dipti Gupta
J. Am. Coll. Cardiol. 2008 52: 567-568.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A33-A34.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. Barbieri, F. Bursi, F. Mantovani, C. Valenti, M. Quaglia, E. Berti, M. Marino, and M. G. Modena
Left ventricular hypertrophy reclassification and death: application of the Recommendation of the American Society of Echocardiography/European Association of Echocardiography
Eur Heart J Cardiovasc Imaging,
January 1, 2012;
13(1):
109 - 117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Y. To, A. Dhillon, and M. Y. Desai
Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol. Img.,
October 1, 2011;
4(10):
1123 - 1137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Y. Desai, S. R. Ommen, W. J. McKenna, H. M. Lever, and P. M. Elliott
Imaging Phenotype Versus Genotype in Hypertrophic Cardiomyopathy
Circ Cardiovasc Imaging,
March 1, 2011;
4(2):
156 - 168.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. Turer, Z. Samad, A. M. Valente, M. A. Parker, B. Hayes, R. J. Kim, J. Kisslo, and A. Wang
Anatomic and clinical correlates of septal morphology in hypertrophic cardiomyopathy
Eur Heart J Cardiovasc Imaging,
February 1, 2011;
12(2):
131 - 139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Salerno and C. M. Kramer
Prognosis in Hypertrophic Cardiomyopathy With Contrast-Enhanced Cardiac Magnetic Resonance: The Future Looks Bright
J. Am. Coll. Cardiol.,
September 7, 2010;
56(11):
888 - 889.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Gebker, J. G. Mirelis, C. Jahnke, T. Hucko, R. Manka, A. Hamdan, B. Schnackenburg, E. Fleck, and I. Paetsch
Influence of Left Ventricular Hypertrophy and Geometry on Diagnostic Accuracy of Wall Motion and Perfusion Magnetic Resonance During Dobutamine Stress
Circ Cardiovasc Imaging,
September 1, 2010;
3(5):
507 - 514.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Alpendurada, J. Wong, and D. J. Pennell
Practical applications of cardiovascular magnetic resonance
Heart Asia,
July 5, 2010;
1(1):
31 - 37.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Pennell
Cardiovascular Magnetic Resonance
Circulation,
February 9, 2010;
121(5):
692 - 705.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. D. Karamitsos, J. M. Francis, S. Myerson, J. B. Selvanayagam, and S. Neubauer
The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure
J. Am. Coll. Cardiol.,
October 6, 2009;
54(15):
1407 - 1424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Maron, B. J. Maron, C. Harrigan, J. Buros, C. M. Gibson, I. Olivotto, L. Biller, J. R. Lesser, J. E. Udelson, W. J. Manning, et al.
Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
220 - 228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. McLeod, M. J. Ackerman, R. A. Nishimura, A. J. Tajik, B. J. Gersh, and S. R. Ommen
Outcome of Patients With Hypertrophic Cardiomyopathy and a Normal Electrocardiogram
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
229 - 233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-Z. Song
Left Ventricular Mass and the Outcome of Patients With Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
399 - 399.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Olivotto, M. S. Maron, F. Cecchi, and B. J. Maron
Reply
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
399 - 399.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Maron and C. Y. Ho
Hypertrophic cardiomyopathy without hypertrophy: an emerging pre-clinical subgroup composed of genetically affected family members.
J. Am. Coll. Cardiol. Img.,
January 1, 2009;
2(1):
65 - 68.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
November 11, 2008;
52(20):
1671 - 1678.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Reichek and D. Gupta
Hypertrophic Cardiomyopathy: Cardiac Magnetic Resonance Imaging Changes the Paradigm
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
567 - 568.
[Full Text]
[PDF]
|
 |
|
|